ALKS vs PFE · P/E 14, rev $1.56B vs P/E 20, rev $62.58B
Alkermes Plc (ALKS) versus Pfizer Inc (PFE) — a side-by-side from cached financials, not a winner call.
Alkermes Plc (ALKS) is a drug manufacturers - specialty & generic company listed on US.
Pfizer Inc (PFE) is a drug manufacturers - general company listed on NYSE. It is led by Albert Bourla.
Latest reported ALKS revenue for 2024-12-31 was $1.56B. Net income was $367.1M. Revenue was down 6.4% from 2023-12-31 to 2024-12-31. ALKS currently screens at market cap $4.78B and trailing P/E 13.8.
Latest reported PFE revenue for 2025-12-31 was $62.58B. Net income was $7.77B. Revenue was down 1.6% from 2024-12-31 to 2025-12-31. PFE currently screens at market cap $147.73B and trailing P/E 19.8.
ALKS currently screens at market cap $4.78B and trailing P/E 13.8. PFE currently screens at market cap $147.73B and trailing P/E 19.8.
Not investment advice. Open the ALKS and PFE stock pages for the full models.
Not investment advice.